Speech assessment in patients with Parkinson's disease and impulse control issues
STIMPulseControl Ancillary Speech Study
This study tests how deep brain stimulation for impulse control in Parkinson's disease affects patients' speech over time.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | University of Kiel Academic / other |
| Locations | 12 sites (Cologne and 11 other locations) |
| Trial ID | NCT06561919 on ClinicalTrials.gov |
What this trial studies
This ancillary study focuses on analyzing the speech of patients enrolled in the main STIMPulseControl study, which investigates the effects of deep brain stimulation on impulse control in Parkinson's disease. Speech recordings will be taken at three time points: before surgery, and at 6 and 12 months post-surgery. The recordings will follow a standardized protocol and will be analyzed for various speech features to assess the impact of surgical and pharmacological interventions on speech and cognitive outcomes. The goal is to understand how these interventions affect motor and emotional aspects of speech in patients with Parkinson's disease.
Who should consider this trial
Good fit: Ideal candidates are patients with Parkinson's disease who are participating in the main STIMPulseControl study and are undergoing deep brain stimulation.
Not a fit: Patients who do not have Parkinson's disease or those not participating in the main STIMPulseControl study may not benefit from this ancillary study.
Why it matters
Potential benefit: If successful, this study could provide insights into the relationship between speech features and cognitive changes in Parkinson's disease, potentially improving treatment strategies.
How similar studies have performed: While this specific approach is part of a larger study, similar studies have shown promise in understanding speech changes in Parkinson's disease, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Please refer to main study (STIMPulseControl KKS-313) Exclusion Criteria: Please refer to main study (STIMPulseControl KKS-313)
Where this trial is running
Cologne and 11 other locations
- University Hospital Cologne — Cologne, Germany (Recruiting)
- University Hospital Carl Gustav Carus — Dresden, Germany (Recruiting)
- University Hospital Duesseldorf — Düsseldorf, Germany (Recruiting)
- University Medical Center Hamburg-Eppendorf — Hamburg, Germany (Recruiting)
- University Hospital Schleswig-Holstein (UKSH), Campus Kiel — Kiel, Germany (Recruiting)
- University Hospital of Giessen and Marburg (UKGM), Campus Marburg — Marburg, Germany (Recruiting)
- Charité Campus Mitte — Mitte, Germany (Recruiting)
- University Hospital Tuebingen — Tübingen, Germany (Recruiting)
- University Hospital Wuerzburg — Würzburg, Germany (Recruiting)
- Amsterdam University Medical Center — Amsterdam, Netherlands (Recruiting)
- University Hospital of Bern (Inselspital) — Bern, Switzerland (Recruiting)
- University Hospital Zuerich (USZ) — Zurich, Switzerland (Recruiting)
Study contacts
- Study coordinator: Steffen Paschen, MD
- Email: steffen.paschen@uksh.de
- Phone: 0049 431 500 23819
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.